MedTrace Logo

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

NCT02468024 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2026-04-16

No results posted yet for this study

Summary

To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

Conditions

Interventions

PROCEDURE

Lung Surgery

Sublobar Lung Resection

RADIATION

Radiation therapy

Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Robert Timmerman, MD · UTSW Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • United States
  • Australia
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02468024 on ClinicalTrials.gov